These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 8549381)

  • 21. Protective effects of sparfloxacin in experimental pneumonia caused by Chlamydia pneumoniae in leukopenic mice.
    Nakata K; Okazaki Y; Hattori H; Nakamura S
    Antimicrob Agents Chemother; 1994 Aug; 38(8):1757-62. PubMed ID: 7986006
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In vitro activities of moxifloxacin and other fluoroquinolones against Mycoplasma pneumoniae.
    Hamamoto K; Shimizu T; Fujimoto N; Zhang Y; Arai S
    Antimicrob Agents Chemother; 2001 Jun; 45(6):1908-10. PubMed ID: 11353651
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparative in vitro susceptibilities and bactericidal activities of investigational fluoroquinolone ABT-492 and other antimicrobial agents against human mycoplasmas and ureaplasmas.
    Waites KB; Crabb DM; Duffy LB
    Antimicrob Agents Chemother; 2003 Dec; 47(12):3973-5. PubMed ID: 14638513
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vitro and in vivo activities of sparfloxacin (AT-4140) against Mycobacterium tuberculosis.
    Ji B; Truffot-Pernot C; Grosset J
    Tubercle; 1991 Sep; 72(3):181-6. PubMed ID: 1663283
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Clinical study on sparfloxacin (SPFX) in the treatment of mycoplasmal pneumonia and penetration of SPFX to the pneumonic lesion].
    Hayashi Y; Ito G; Takeyama S
    Kansenshogaku Zasshi; 1998 Jan; 72(1):54-9. PubMed ID: 9503785
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Efficacy of lomefloxacin and ofloxacin in complex therapy of infections in patients with burns].
    Krutikov MG; Alekseev AA; Bobrovnikov AE; Grishina IA; Elagina LV; Izotova GN; Iakovlev VP
    Antibiot Khimioter; 1998; 43(10):27-31. PubMed ID: 9825107
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of in-vitro activity of new quinolones, macrolides, and minocycline against Mycoplasma pneumoniae.
    Sato K
    J Infect Chemother; 2000 Sep; 6(3):188. PubMed ID: 11810563
    [No Abstract]   [Full Text] [Related]  

  • 28. Grepafloxacin--a new fluoroquinolone.
    Med Lett Drugs Ther; 1998 Jan; 40(1019):17-8. PubMed ID: 9465856
    [No Abstract]   [Full Text] [Related]  

  • 29. In vitro and in vivo antichlamydial activities of HSR-903, a new fluoroquinolone antibiotic.
    Niki Y; Miyashita N; Kubota Y; Nakajima M; Matsushima T
    Antimicrob Agents Chemother; 1997 Apr; 41(4):857-9. PubMed ID: 9087506
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sparfloxacin and levofloxacin.
    Med Lett Drugs Ther; 1997 Apr; 39(999):41-3. PubMed ID: 9137295
    [No Abstract]   [Full Text] [Related]  

  • 31. Mycoplasma pneumoniae isolated from patients with respiratory infection in Kanagawa Prefecture in 1976-2006: emergence of macrolide-resistant strains.
    Okazaki N; Ohya H; Sasaki T
    Jpn J Infect Dis; 2007 Sep; 60(5):325-6. PubMed ID: 17881881
    [No Abstract]   [Full Text] [Related]  

  • 32. The new 4-quinolones DU-6859a and DV-7751a show enhanced activity against Streptococcus pneumoniae.
    Morrissey I; Smith JT
    Drugs; 1995; 49 Suppl 2():228-9. PubMed ID: 8549312
    [No Abstract]   [Full Text] [Related]  

  • 33. Antimycoplasmal activities of new quinolones, tetracyclines, and macrolides against Mycoplasma pneumoniae.
    Arai S; Gohara Y; Kuwano K; Kawashima T
    Antimicrob Agents Chemother; 1992 Jun; 36(6):1322-4. PubMed ID: 1416832
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In vitro activity of midecamycin diacetate against Mycoplasma pneumoniae and Chlamydia pneumoniae.
    Pereyre S; de Barbeyrac B; Renaudin H; Poutiers F; Bébéar C; Bébéar CM
    J Antimicrob Chemother; 2001 Feb; 47(2):240-1. PubMed ID: 11157917
    [No Abstract]   [Full Text] [Related]  

  • 35. [Fundamental studies of josamycin against Mycoplasma pneumoniae (author's transl)].
    Izumikawa K; Komori M; Tomita H; Sai M; Suyama N; Iwasaki H; Fukui M; Hara K
    Jpn J Antibiot; 1981 Sep; 34(9):1288-91. PubMed ID: 6799669
    [No Abstract]   [Full Text] [Related]  

  • 36. Sparfloxacin in the treatment of males with urethritis.
    Tanaka M; Matsumoto T; Kumazawa J; Nagayama A
    Eur J Clin Microbiol Infect Dis; 1992 Jul; 11(7):660. PubMed ID: 1327790
    [No Abstract]   [Full Text] [Related]  

  • 37. The effect of antibiotics on Mycoplasma pneumoniae in vitro and in vivo.
    Slotkin RI; Clyde WA; Denny FW
    Am J Epidemiol; 1967 Jul; 86(1):225-37. PubMed ID: 5006447
    [No Abstract]   [Full Text] [Related]  

  • 38. Sparfloxacin is more bactericidal than ofloxacin against Mycobacterium leprae in mice.
    Franzblau SG; Parrilla ML; Chan GP
    Int J Lepr Other Mycobact Dis; 1993 Mar; 61(1):66-9. PubMed ID: 8392100
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Community-acquired macrolide-resistant Mycoplasma pneumoniae pneumonia in patients more than 18 years of age.
    Miyashita N; Maruyama T; Kobayashi T; Kobayashi H; Taguchi O; Kawai Y; Yamaguchi T; Ouchi K; Oka M
    J Infect Chemother; 2011 Feb; 17(1):114-8. PubMed ID: 20676912
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparative susceptibility of Mycoplasma pneumoniae to erythromycin, ciprofloxacin, and lomefloxacin.
    Cassell GH; Waites KB; Pate MS; Canupp KC; Duffy LB
    Diagn Microbiol Infect Dis; 1989; 12(5):433-5. PubMed ID: 2515025
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.